SandboxAQ Unveils Synthetic Data Platform Backed by NVIDIA to Revolutionize AI-Driven Drug Discovery

Intelligent Finance APP learned that SandboxAQ, an AI startup spun off from Google's parent company Alphabet (GOOGL.US) and strategically supported by NVIDIA (NVDA.US), officially released a large-scale synthetic dataset on June 18 local time. The aim is to accelerate the global new drug development process by simulating the interaction mechanism between drug molecules and proteins. This tech newcomer, which has raised nearly 1 billion US dollars in cumulative financing, is attempting to break the spatiotemporal limitations of traditional laboratory research and reconstruct the underlying logic of drug screening with computing power.

Unlike the traditional approach that relies on physical experiments to obtain data, SandboxAQ has innovatively integrated computational chemistry with artificial intelligence. The company's algorithm platform, built on Nvidia's high-performance chips, generated 5.2 million three-dimensional molecular structures that have not yet been observed in the real world by solving quantum mechanical equations describing interatomic forces. These "virtual molecules," though not synthesized in a lab, strictly follow physical laws in terms of spatial configuration and chemical properties, effectively creating a vast molecular library in the digital realm.

"This resolves a core pain point in the pharmaceutical research and development field that has persisted for decades." Nadia Hachen, head of SandboxAQ's AI simulation business, revealed that when researchers identify a disease-related protein as a drug target, they can use this platform to quickly screen out candidate molecules theoretically capable of binding. Compared to the limitations of traditional computer-aided drug design, which can only handle a limited number of molecular combinations, the newly released synthetic dataset can increase prediction efficiency by several orders of magnitude. Moreover, the prediction results align with real biological experiments to meet laboratory standards.

This innovative paradigm is reshaping the early stages of drug development. Take cancer treatment as an example: if a research team attempts to block a key protein that promotes cancer cell proliferation, traditional methods would require synthesizing and testing tens of thousands of molecules in the lab, a process that could take years. However, with SandboxAQ's technology, researchers can directly simulate the interactions between billions of molecules and the target protein in virtual space, reducing the screening period to weeks and significantly lowering the time and financial costs of new drug development.

Notably, while the company offers free access to its synthetic datasets for academic institutions, it adopts a commercial approach for AI predictive models trained on this data. This "open-source data + paid model" hybrid strategy not only advances foundational industry research but also establishes a sustainable technological barrier. As investment in AI drug discovery continues to rise within the biopharmaceutical sector, this tech newcomer, born in Silicon Valley, is striving to carve out a new path in the trillion-dollar pharmaceutical R&D market.